

Part II Organizational Action (continued)


17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ Internal Revenue Code Sections 1001 and 1012.

18 Can any resulting loss be recognized? ▶ Yes.

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ See attached statement

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here

Signature ▶  Date ▶ JANUARY 11, 2017

Print your name ▶ BEN HARSHBARGER Title ▶ GENERAL COUNSEL

Paid Preparer Use Only

Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
Firm's name ▶			Firm's EIN ▶	
Firm's address ▶			Phone no.	

**Novellon Therapeutics Inc.
Form 8937**

Part II:

14. On November 29, 2016, a wholly owned indirect subsidiary of Novellon Therapeutics Inc. (a Canadian corporation) merged with and into Aegerion Pharmaceuticals, Inc., with Aegerion Pharmaceuticals, Inc. surviving as a wholly owned indirect subsidiary of Novellon Therapeutics Inc. (the "Merger"). Pursuant to the Merger, each share of Aegerion Pharmaceuticals, Inc. common stock issued and outstanding immediately prior to the effective time of the Merger was canceled and automatically converted into and became the right to receive 1.0256 Novellon Therapeutics Inc. ordinary shares.

15. Novellon Therapeutics Inc. believes that the receipt of the Novellon Therapeutics Inc. ordinary shares in exchange for shares of Aegerion Pharmaceuticals, Inc. common stock pursuant to the Merger was a taxable transaction for U.S. federal income tax purposes. Therefore, generally, an Aegerion Pharmaceuticals, Inc. shareholder recognized capital gain or loss equal to the difference between (i) the shareholder's adjusted tax basis in the shares of Aegerion Pharmaceuticals, Inc. common stock exchanged and (ii) the fair market value of the Novellon Therapeutics Inc. ordinary shares received in the Merger. A shareholder's adjusted tax basis in the shares of Aegerion Pharmaceuticals, Inc. common stock generally should have equaled the shareholder's purchase price.

An Aegerion Pharmaceuticals, Inc. shareholder receiving Novellon Therapeutics Inc. ordinary shares pursuant to the Merger will have an initial tax basis in those Novellon Therapeutics Inc. ordinary shares equal to the fair market value of the Aegerion Pharmaceuticals, Inc. common stock exchanged therefor.

16. Novellon Therapeutics Inc. intends to take the position in all applicable tax filings that the fair market value of each share of Aegerion Pharmaceuticals, Inc. common stock and each Novellon Therapeutics Inc. ordinary share, each at the time of Merger, was equal to \$2.0893, which was the per share volume-weighted average price of Aegerion Pharmaceuticals, Inc. stock as displayed under the heading VWAP Bloomberg on the Bloomberg page for Aegerion Pharmaceuticals, Inc. for the date of the Merger (November 29, 2016). Each holder of Aegerion Pharmaceuticals, Inc. common stock or Novellon Therapeutics Inc. ordinary shares should consult his or her own tax advisor as to the fair market value of the shares exchanged in the Merger.

19. The reportable year for this taxable transaction is the calendar year 2016 or the fiscal year inclusive of November 29, 2016.

The U.S. Federal income tax consequences discussed in this Form 8937 are for general information only and do not constitute tax advice to any holder of Aegerion Pharmaceuticals, Inc. common stock or Novellon Therapeutics Inc. ordinary shares. Each holder of Aegerion Pharmaceuticals, Inc. common stock or Novellon Therapeutics Inc. ordinary shares should consult his or her own tax advisor as to the particular consequences that may apply to the holder. For a more detailed description about the tax consequences

of the merger, please see “MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER” in the proxy statement/prospectus Aegerion Pharmaceuticals, Inc. filed with the SEC on October 6, 2016.